COMPASS Pathways said it has completed the NDA filing for COMP360 for treatment-resistant depression, holds a national priority voucher, and expects the FDA review to conclude within one to two months of submission completion. The company said it will be launch-ready by year-end, with launch expected in the first half of next year subject to approval. It expects COMP360 to require two to four annual doses versus 35 to 55 for Spravato.
CMPS · COMPASS Pathways plc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Compass Pathways has completed its FDA filing for COMP360, its synthetic psilocybin for treatment-resistant depression, supported by two Phase III studies enrolling close to 900 patients. It expects to be launch ready by the end of the year and to launch in the first half of next year, subject to approval. Management said about 93% of the population lives in states that will reschedule within 30 days.
COMPASS Pathways submitted the Comp360 NDA for treatment-resistant depression, plans to be launch ready by the end of the year, and expects initial revenue in late Q2, Q3 next year.
COMPASS Pathways completed its NDA submission for treatment-resistant depression. It targets launch readiness by the end of the year and expects revenue to begin around late Q2 or Q3 next year.
COMPASS Pathways said its rolling NDA submission will be filed in the next two weeks, supporting an expected H12027 launch subject to FDA approval. The company ended the third quarter with $444 million in cash, expected to fund operations into 2028.
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. Compass Pathways reported positive Phase 3 data for COMP360 in TRD with durability through six months and an ongoing rolling NDA submission targeted for completion in Q4, with commercial launch anticipated in the first half of 2027, supported by $433 million in cash expected to fund operations into 2028. Net loss widened sharply to $253.8 million in Q2 from $38.4 million a year ago, driven by $205.6 million in non-cash warrant fair value adjustments.
- + Rolling NDA submission is underway with FDA review in progress and final submission on track for Q4 2026.
- + Cash position of $433 million is expected to fund operations well beyond launch and into 2028.
- + Approximately 90% of interventional psychiatrists indicated willingness to prescribe COMP360 within the first year of availability.
- + R&D expenses declined to $29.2 million in Q2 2026 from $30.3 million in Q2 2025 as Phase 3 costs tapered.
- − Q2 net loss widened sharply to $253.8 million ($1.88/share) from $38.4 million a year earlier, primarily due to a $205.6 million non-cash warrant fair value loss.
- − G&A expenses rose to $23.2 million in Q2 2026 from $12.6 million a year earlier as commercial preparedness spending ramped.
- − Launch remains dependent on FDA approval and subsequent DEA and state-level rescheduling, creating timing uncertainty.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CMPS
this stock
COMPASS Pathways plc
|
$1.15B | +17.7% | — | — | 12.1% |
|
HCA
HCA Healthcare, Inc.
|
$97.59B | +2.0% | +7.1% | 15.8 | 2.3% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$33.07B | +2.4% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$21.60B | +36.5% | +0.9% | 7.9 | 2.2% |
|
EHC
Encompass Health Corp
|
$13.24B | +27.1% | +10.5% | 21.1 | 3.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 19, 2026
- This year
- 24
COMPASS Pathways said it has completed the NDA filing for COMP360 for treatment-resistant depression, holds a national priority voucher, and expects the FDA review to conclude within one to two months of submission completion. The company said it will be launch-ready by year-end, with launch expected in the first half of next year subject to approval. It expects COMP360 to require two to four annual doses versus 35 to 55 for Spravato.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CMPS | -12.7% | -31.4% | -37.8% | -29.8% | +17.7% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | -8.8% | -25.9% | -34.4% | -26.4% | +10.6% |